Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Nicootec is a Japanese biotechnology startup and a spin-off from Nagoya University, specializing in the isolation and analysis of extracellular vesicles (EVs), commonly known as exosomes. The company utilizes a proprietary nanowire-based technology platform to efficiently capture and analyze EVs from small volumes of biological fluids, such as blood or urine. This platform is primarily aimed at developing highly sensitive liquid biopsy diagnostics for early cancer detection and monitoring, addressing the limitations of traditional purification methods. Beyond diagnostics, Nicootec is exploring the potential of EVs in therapeutic applications and drug delivery systems. The company's innovative approach positions it as a key player in the emerging field of exosome-based medicine. By leveraging its unique nanowire technology, Nicootec aims to provide non-invasive and precise medical solutions for various diseases, starting with oncology.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Nicootec.